Cogent Biosciences, Inc. · NASDAQ:COGT
Cogent Biosciences — Unum Therapeutics — Merger or Acquisition (July 2020)
22 slides from Cogent Biosciences's merger presentation, Jul 6, 2020
Slide 1: Kiq Acquisition July 2020
KIQ aCQUISITION July 2020 Exhibit 99.2
Slide 2: Forward-Looking Statements and Risk Factors
Forward-Looking Statements and Risk Factors This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: uses of proceeds; projected cash runways; future product development plan
Slide 3: Acquisition of Kiq LLC and Financing
Acquisition of Kiq LLC and Financing Structured as a stock-for-stock transaction where all of Kiq’s outstanding equity interests were exchanged for a combination of shares of Unum common stock and shares of a newly created Series A non-voting convertible preferred stock Concurrent with the acquisiti
Slide 4: Acquisition of Kiq LLC and Financing (cont'd)
Acquisition of Kiq LLC and Financing (cont’d) Seeking to advance best-in-class precision kinase inhibitors while pursuing strategic opportunities for cell-based therapies Focused on clinical development of PLX9486, a highly potent and selective KIT D816V inhibitor To be studied as a monotherapy in p
Slide 5: Vision to Build a Fully Integrated Precision Kinase Company
Vision to Build a Fully Integrated Precision Kinase Company With a Clinical Program to Anchor Efforts PLX9486, a potential best-in-class KIT D816V inhibitor, is a foundational program with promising preliminary clinical efficacy and a favorable safety profile in gastrointestinal stromal tumors (GIST
Slide 6: Lead Program PLX9486 Is a Highly Selective and Potent KIT Mutant Inhibitor
Lead Program PLX9486 Is a Highly Selective and Potent KIT Mutant Inhibitor with a Potentially Best-in-Class Clinical Profile Highly Selective and Potent for KIT Exon 17 / D816V 11 months median PFS shown in 18 2L+ GIST patients treated with PLX9486 in combination with sunitinib Single agent & combin
Slide 7: By Design, PLX9486 Has Selectivity and Potency to KIT D816V
Enzyme PLX9486 c-Kit (wt) >5000* c-Kit (D816V) 1.125 FMS 602.4 KDR/VEGFR2 >5000* PDGFRα >5000* PDGFRα (D842V) 104.3 By Design, PLX9486 Has Selectivity and Potency to KIT D816V PLX9486 is Type I Inhibitor designed to selectively bind the active conformation of mutant KIT D816V Select IC50 values (nM)
Slide 8: PLX9486 Future Clinical Programs
PLX9486 FUTURE CLINICAL PROGRAMS Advanced Systemic Mastocytosis (ASM) Indolent Systemic Mastocytosis (ISM)
Slide 9: Both Advanced SM and Indolent SM are Primarily Driven by D816V Mutations
Both Advanced SM and Indolent SM are Primarily Driven by D816V Mutations The most common KIT mutation in patients with systemic mastocytosis, aspartate to valine at residue 816 (D816V), lies within the activation loop domain and causes a conformational change in the enzymatic pocket of the receptor
Slide 10: Unmet Need in ASM and ISM
Advanced Systemic Mastocytosis Median survival of approximately ≤3.5 years FDA approved drug, Rydapt (Midostaurin), broad spectrum TKI, challenging tolerability Indolent and Smoldering Mastocytosis Poor quality of life No approved therapies: current treatments include H1 and H2 anti-histamines, mast
Slide 11: Encouraging Tolerability Profile as Single Agent and Supports Clinical Trials in Mastocytosis
Encouraging Tolerability Profile as Single Agent and Supports Clinical Trials in Mastocytosis Single Agent PLX9486 (All Doses) in Advanced Cancer and GIST Patients Single agent PLX9486 human safety data in advanced cancer and GIST patients shows a promising profile for a chronic indication such as s
Slide 12: Preliminary Plans: ASM and ISM Registration Clinical Program Design
Preliminary Plans: ASM and ISM Registration Clinical Program Design Global Advanced Systemic Mastocytosis (ASM) Program [Subject to Regulatory Feedback] Global Indolent Systemic Mastocytosis (ISM) Program [Subject to Regulatory Feedback] PLX9486 Dose Finding Arms Single Arm Pivotal Study Phase 2a Do
Slide 13: PLX9486 Program: GIST
PLX9486 Program: GIST eg UNUM 13
Slide 14: PLX9486 and Sunitinib Combination Tackle GIST Heterogeneity
PLX9486 and Sunitinib Combination Tackle GIST Heterogeneity by Targeting Exon 13 and Exon 17 Simultaneously EX8 EX9 EX11 EX13 EX14 EX18 EX17 JM ATP Binding Activation Loop
Slide 15: Mutations in Exon 13 and Exon 17 Are Key Drivers of Resistance
Mutations in Exon 13 and Exon 17 are Key Drivers of Resistance Imatinib Primary mutations: Exon 9 / Exon 11 Sunitinib Regorafenib Ripretinib ORR ~60% PFS ~19 months ORR ~7% PFS ~6 months ORR ~5% PFS ~4.8 months ORR ~9% PFS ~6.3 months 1L 2L 3L 4L Avapritinib approved for PDGFRα Exon 18 mutations (~
Slide 16: Dual-conformation KIT Inhibition Drives Tumor Regression in GIST Mouse Models
Dual-conformation KIT Inhibition Drives Tumor Regression in Heterogeneous GIST mouse models Ex11 (W557_K558del), Ex17 (N822K) Ex13 (K642E), Ex17 (D823Y)
Slide 17: PLX9486 Has Completed a P1b/2a Trial in GIST with Encouraging Results
PLX9486 Has Completed a P1b/2a Trial in GIST with Encouraging Results Phase 1b: Advanced Solid Tumors, Primarily GIST PLX9486 Single Agent Dose Escalation (n=24) Study Objectives Safety and PK Single agent MTD/RP2D Efficacy including ORR (RECIST 1.1), DOR and PFS Phase 2a: Previously treated GIST PL
Slide 18: PLX9486 Has Completed a P1b/2a Trial in GIST with Encouraging Results
PLX9486 Has Completed a P1b/2a Trial in GIST with Encouraging Results 0.00 0.25 0.50 0.75 1.00 0 4 8 12 16 20 24 28 Progression Free Survival (months) PFS probability (GIST Patients) Strata PLX9486 +Sunitinb 18 13 11 7 6 3 1 0 PLX9486 +Sunitinb Number at risk PLX9486 + sunitinib has shown median PFS
Slide 19: Encouraging Tolerability in Combination With Sunitinib
Encouraging Tolerability in Combination With Sunitinib Gives Us Confidence to Move Forward Into a Pivotal Study* Select sunitinib single agent AEs (GIST) Diarrhea — 40% Anorexia – 33% Skin discoloration – 30% Mucositis/stomatitis – 29% Preferred Term Total (n=17) Any Grade CTCAE ≥3 Subjects reportin
Slide 20: Preliminary Plans: Sunitinib +/- PLX9486 Registrational Programs
Preliminary Plans: Sunitinib +/- PLX9486 Registrational Programs Phase 1b/2a data planned for presentation at an upcoming medical conference PLX9486 + sunitinib Phase III Refractory GIST (under consideration – seeking FDA feedback) Patient Population: Late line GIST Primary Endpoint: PFS Secondary E
Slide 21: Unum's Lead Program PLX9486 Can Rapidly Move Into 3 Mid-to-Late Stage Trials
Unum’s Lead Program PLX9486 Has Phase 2 Data and Can Rapidly Move Into 3 Mid-to-Late Stage Clinical Trials Phase 3 start in GIST in combination with sunitinib (2H’2021) Phase 2 start as single agent in Indolent Systemic Mastocytosis (2H’2021) Phase 2 start as single agent in Advanced Systemic Mastoc
Slide 22: Thank you
Thank you unumrx.com Unum Therapeutics Inc. | 200 Cambridge Park Drive Suite 3100 | Cambridge, MA 02140 USA
Unum Therapeutics — Merger or Acquisition (July 2020) on 6ix